21:55 , Oct 8, 2018 |  BC Extra  |  Company News

Management tracks: As Akcea shifts to commercialization, Crooke resigns from board

Akcea Therapeutics Inc. (NASDAQ:AKCA) said Stanley Crooke, founder, chairman and CEO of parent company Ionis Pharmaceuticals Inc. (NASDAQ:IONS), resigned from Akcea's board. Ionis CBO Damien McDevitt will take Crooke's place on Akcea's board. An Ionis...
00:08 , Jun 26, 2018 |  BC Extra  |  Politics & Policy

Fresh challenge for Chinese investment in U.S. biopharma

The momentum of Chinese investment in the U.S. biopharma industry could be at risk as Trump administration officials made conflicting statements Monday as to whether the administration is considering restrictions on foreign investments in U.S....
20:08 , Jun 1, 2018 |  BioCentury  |  Finance

Distribution to innovation

Chinese drug distributor Sinopharm plans to close additional renminbi and U.S. dollar funds this year to back innovative biotechs. According to Sinopharm Capital’s Liang Deng, China National Pharmaceutical Group Corp. (Sinopharm) is the largest pharmaceutical...
20:06 , May 18, 2018 |  BioCentury  |  Finance

Ansun’s China ambitions

The China-heavy syndicate behind Ansun BioPharma Inc.’s $85 million series A round reflects the San Diego-based antiviral company’s long-term plans to penetrate the China market. Sinopharm Healthcare Fund and Lilly Asia Ventures led the round,...
02:29 , May 18, 2018 |  BC Week In Review  |  Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

Ansun BioPharma Inc. (San Diego, Calif.) raised on May 14 a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China,...
15:02 , May 14, 2018 |  BC Extra  |  Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

Ansun BioPharma Inc. (San Diego, Calif.) raised a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital,...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

Fludase: Clinical trial data

Data from a transplant patient on a respirator co-infected with influenza and parainfluenza who was treated with a 5-day course of DAS181 under a compassionate use emergency IND showed that the compound reduced oxygen requirement....
07:00 , Aug 22, 2011 |  BC Week In Review  |  Clinical News

Fludase: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 177 evaluable patients with PCR-confirmed influenza infection showed that once-daily 10 mg DAS181 for 3 days significantly reduced viral load in respiratory secretions, the primary...
08:00 , Feb 21, 2011 |  BC Week In Review  |  Clinical News

Fludase infectious data

NexBio reported data from a single bone marrow transplant patient with PIV-3 infection showing that treatment with DAS181 under emergency-use IND provisions improved the patient's respiratory status within 1 day. By day 3, the patient...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

NexBio preclinical data

In mice, 0.06, 0.1 and 0.6 mg/kg once-daily DAS181 for 3 days significantly reduced airway resistance following challenge with methacholine vs. saline-treated controls (p<0.05 for all). Data were presented at the American College of Allergy,...